Medically reviewed by Mary Choy, PharmDMedically reviewed by Mary Choy, PharmD Trileptal (oxcarbazepine) is an anticonvulsant drug approved by the U.S. Food and Drug Administration (FDA) to treat ...

Trileptal is an anti-seizure medication that doctors may prescribe off-label for people with bipolar disorder. It is the branded version of oxcarbazepine and may help treat mania and depression.

Oxcarbazepine 300mg/5mL; plum-lemon flavor; contains alcohol. Off-white to slightly brown or slightly red suspension. Available in amber glass bottles containing 250 mL of oral suspension. Supplied ...

Novartis (NVS) gave research funds to a doctor who advocated using the anti-seizure drug Trileptal as an anti-bipolar depression treatment in children -- an unapproved use of that drug-- the company ...

June 15, 2005 — The U.S. Food and Drug Administration (FDA) approved in March revisions to safety labeling to advise that use of lomefloxacin HCl tablets is associated with a risk of peripheral ...

Novartis announced that the European Mutual Recognition Procedure for its oral suspension formulation of Trileptal (oxcarbazepine) has been completed. The new product will become available as soon as ...

April 20, 2005 -- The U.S. Food and Drug Administration (FDA) and Novartis Pharmaceuticals Corp have warned healthcare professionals of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal ...

Novartis AG’s epilepsy drug Trileptal has a new warning about life-threatening skin reactions reported by patients who took the medicine, the company and the Food and Drug Administration said.

BASEL, Switzerland, Jan 26 (Reuters) - Novartis will plead guilty to violating U.S. laws relating to potential off-label marketing and promotion of an epilepsy treatment and pay a $185 million fine, ...

Two Indian pharma companies got the FDA's approval to sell generic forms of the Novartis epilepsy drug Trileptal. Sun Pharma and Glenmark Pharmaceuticals, both based in Mumbai, are OK'd to market the ...